Text Size

Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy

This study has been completed.
Sponsor:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00765232
First received: September 30, 2008
Last updated: December 21, 2011
Last verified: December 2011
History of Changes
Results First Received: November 18, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Nephrectomy
Laparoscopic Donor Nephrectomy
Interventions: Drug: Ketorolac
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited from October 2008 to November 2010.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ketorolac 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Placebo 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.

Participant Flow:   Overall Study
    Ketorolac     Placebo  
STARTED     57     54  
COMPLETED     57     54  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Ketorolac 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Placebo 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Total Total of all reporting groups

Baseline Measures
    Ketorolac     Placebo     Total  
Number of Participants  
[units: participants]
 		  57     54     111  
Age  
[units: years]
Mean ± Standard Deviation 		  43  ± 11     43  ± 13     43  ± 12  
Gender  
[units: participants]
 		     
Female     23     33     56  
Male     34     21     55  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Pain 'Right Now'   [ Time Frame: 24 hours after the end of surgery ]
  Show Outcome Measure 1

2.  Primary:   Morphine Equivalents of Concomitant Pain Medication   [ Time Frame: 24 hours after the end of surgery ]
  Show Outcome Measure 2


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Mitchell R. Humphreys MD
Organization: Mayo Clinic
phone: 480-301-8000
e-mail: humphreys.mitchell@mayo.edu


No publications provided by Mayo Clinic

Publications automatically indexed to this study:


Responsible Party: Mitchell R. Humphreys, M.D., Mayo Clinic
ClinicalTrials.gov Identifier: NCT00765232     History of Changes
Other Study ID Numbers: 08-000747 LDN
Study First Received: September 30, 2008
Results First Received: November 18, 2011
Last Updated: December 21, 2011
Health Authority: United States: Institutional Review Board